Prelude Therapeutics

Company snapshot

Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline features highly selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors – new approaches to clinically validated targets with transformative potential for patients. We are also leveraging our expertise in targeted protein degrada

• 13 active pipeline program(s) linked via ClinicalTrials.gov.
• 16 US patent(s) indexed to this assignee profile.
• 13 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Prelude Therapeutics. Not investment advice.

• Peer + 0 momentum

  First People's Hospital

  TA overlap score 50

• Peer + 0 momentum

  Teva Pharma

  TA overlap score 40

• Peer + 0 momentum

  Chinese Academy of

  TA overlap score 40

• Peer + 0 momentum

  BEONE MEDICINES AUS

  TA overlap score 40

• Peer + 0 momentum

  Jazz Pharmaceuticals Ireland

  TA overlap score 40

• Peer + 0 momentum

  AbbVie Deutschland GmbH

  TA overlap score 40

• Peer + 0 momentum

  Karyopharm Therapeutics

  TA overlap score 36.4

• Peer + 0 momentum

  Syndax Pharmaceuticals

  TA overlap score 29.4

• Peer + 0 momentum

  PUMA BIOTECHNOLOGY

  TA overlap score 28

• Peer + 0 momentum

  ADC Therapeutics

  TA overlap score 26

Recent activity

Latest pipeline, patent, and corporate events for Prelude Therapeutics.

1. Jun 8, 2026 Clinical update

   PRT3789-02 — Phase 2

2. Jun 8, 2026 Clinical update

   PRT7732-01 — Phase 1

3. Jun 5, 2026 Clinical update

   PRT543 — Phase 1

4. May 23, 2026 Clinical update

   PRT3789 — Phase 2

5. May 23, 2026 Clinical update

   PRT12396 — Phase 1

View all clinical trial activity →

• What is Prelude Therapeutics?

  Prelude Therapeutics is a pharma organization headquartered in Wilmington, USA. It trades on NYSE under ticker PRLD. Primary therapeutic focus areas include Advanced Solid Tumor, Sarcoma, Acute Myeloid Leukemia, Polycythemia Vera (PV), Multiple Myeloma. NovaPharmaNews links 13 cl

• Is Prelude Therapeutics publicly traded?

  Yes. Prelude Therapeutics is listed with ticker PRLD on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Prelude Therapeutics develop or market?

  We link 5 drug profile(s) where Prelude Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/prelude-therapeutics-inc#company-drugs.

• What are the latest developments for Prelude Therapeutics?

  In the last 12 months our linked public records show 13 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Prelude Therapeutics focus on?

  Prelude Therapeutics focuses on Advanced Solid Tumor, Sarcoma, Acute Myeloid Leukemia based on our analysis of their pipeline programs and drug development activities.